Key result
Africa accounts for ~60% of global acute flaccid paralysis cases driven by cVDPV2 genetic emergences.
Why the study?
Despite eradication efforts, poliovirus is re-emerging in Africa due to poor sanitation, vaccine hesitancy, new transmission routes, and poor surveillance.
Africa bears the highest burden of cVDPV2 cases, highlighting the need for collaborative public health efforts, improved sanitation, and mass vaccination to achieve herd immunity.
Enhanced cVDPV2 surveillance may aid outbreak control in Africa; leaves open optimal eradication strategies pending higher-level evidence.
Background and Aim: Poliovirus is a global health issue that affects children in different parts of the world. Despite the efforts of national, international, and nongovernmental organizations to eradicate the disease, it is re-emerging in Africa due to poor sanitation, vaccine hesitancy, new ways of transmission, and poor surveillance among others. Circulating vaccine-derived poliovirus type 2 (cVDPV2) is a major step in eradicating poliovirus and preventing outbreaks in developing countries. Strengthening African healthcare systems, increasing surveillance, hygiene and sanitation, and proper mass vaccination to achieve herd immunity are required in the fight against polio disease. This paper discusses the outbreak of cVDPV2, public health challenges, and recommendations in Africa with a special emphasis on Nigeria. Methods: We searched for articles documenting the incidence of cVDPV2 in Nigeria and other African countries on Pubmed, Google Scholar, and Scopus. Results: A total of 68 distinct cVDPV2 genetic emergences were found across 34 nations between April 2016 to December 2020, and in Nigeria, three cVDPV2 emergences were found. Also, 1596 instances of acute flaccid paralysis linked to cVDPV2 outbreaks were reported in four areas of the World Health Organization where Africa contributed 962 cases out of 1596 cases. Available data indicate that Africa has the most cVDPV2 cases and is associated with various challenges like the unidentified virus source, poor sanitation system, and inability to achieve herd immunity of the cVDPV2 vaccine. Conclusion: Collaborative efforts of stakeholders are crucial in combating infectious diseases, especially those transmitted via environments such as water and air, like poliovirus. Therefore, a collaboration between environmental health workers, veterinarians, community health workers, laboratory scientists, policymakers, and other professionals is required.
No takes yet. Share an insight, caveat, or question.
Adesola et al. (2023) conducted a review in Circulating vaccine-derived poliovirus type 2 (cVDPV2) (n=1,596). cVDPV2 was evaluated on Incidence of cVDPV2 and acute flaccid paralysis. Between April 2016 and December 2020, 68 distinct cVDPV2 genetic emergences occurred across 34 nations, with Africa accounting for 962 of 1,596 global cases of acute flaccid paralysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: